-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, I7CXrsADSC3+orObMBmDJRQ0U+qbBUldliycOU/A8zJkX1T0qghx/SlyEBAXmCX5 +5bbR7LaCM38UPw/UFt59A== /in/edgar/work/0000929624-00-001476/0000929624-00-001476.txt : 20001027 0000929624-00-001476.hdr.sgml : 20001027 ACCESSION NUMBER: 0000929624-00-001476 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 20001026 GROUP MEMBERS: GENSTAR CAPITAL LLC GROUP MEMBERS: GENSTAR CAPITAL PARTNERS II, L.P. GROUP MEMBERS: JEAN-PIERRE L. CONTE GROUP MEMBERS: RICHARD D. PATERSON GROUP MEMBERS: RICHARD F. HOSKINS GROUP MEMBERS: ROBERT J. WELTMAN GROUP MEMBERS: STARGEN II LLC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BIOSOURCE INTERNATIONAL INC CENTRAL INDEX KEY: 0000860451 STANDARD INDUSTRIAL CLASSIFICATION: [2835 ] IRS NUMBER: 770340829 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-52879 FILM NUMBER: 746567 BUSINESS ADDRESS: STREET 1: 820 FLYNN RD STE A CITY: CAMARILLO STATE: CA ZIP: 93012 BUSINESS PHONE: 8059870086 MAIL ADDRESS: STREET 1: 820 FLYNN ROAD CITY: CAMARILLO STATE: CA ZIP: 93012 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GENSTAR CAPITAL LLC CENTRAL INDEX KEY: 0001103633 STANDARD INDUSTRIAL CLASSIFICATION: [ ] FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 585 CALIFORNIA STREET SUITE 4650 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 4158342350 MAIL ADDRESS: STREET 1: 585 CALIFORNIA STREET SUITE 4650 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 SC 13D/A 1 0001.txt SCHEDULE 13D - AMENDMENT #5 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________ SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 5) BioSource International, Inc. __________________ (Name of Issuer) Common Stock, par value $0.001 per share ___________________________ (Title of Class of Securities) 09066H104 --------- (CUSIP Number) Genstar Capital LLC 555 California Street, Suite 4850 San Francisco, California 94104 (415) 834-2350 ______________________________________________ (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) Copy to: Scott R. Haber Latham & Watkins 505 Montgomery Street, Suite 1900 San Francisco, California 94111-2562 (415) 391-0600 October 25, 2000 __________________________________________________ (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this statement because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box [ ]. (Continued on following pages) SCHEDULE 13D - --------------------------------- -------------------------- CUSIP NO. 09066H104 Page 2 of 14 Pages - --------------------------------- -------------------------- - ------------------------------------------------------------------------------ 1. Name of Reporting Person Genstar Capital LLC - ------------------------------------------------------------------------------ 2. Check the Appropriate Box if a Member of a Group (a) [_] (b) [X] - ------------------------------------------------------------------------------ 3. SEC Use Only - ------------------------------------------------------------------------------ 4. Source of Funds AF,OO - ------------------------------------------------------------------------------ 5. Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [_] - ------------------------------------------------------------------------------ 6. Citizenship or Place of Organization Delaware - ------------------------------------------------------------------------------ 7. Sole Voting Power Number of -0- shares of Common Stock Shares ----------------------------------------------------------- 8. Shared Voting Power Beneficially -3,200,553- shares of Common Stock (includes 1,262,542 Owned By shares of Common Stock issuable upon exercise of Warrants) ----------------------------------------------------------- Each 9. Sole Dispositive Power Reporting -0- shares of Common Stock Person ----------------------------------------------------------- 10. Shared Dispositive Power With -3,200,553- shares of Common Stock (includes 1,262,542 shares of Common Stock issuable upon exercise of Warrants) - ------------------------------------------------------------------------------ 11. Aggregate Amount Beneficially Owned by Each Reporting Person -3,200,553- shares of Common Stock (includes 1,262,542 shares of Common Stock issuable upon exercise of Warrants) - ------------------------------------------------------------------------------ 12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [_] - ------------------------------------------------------------------------------ 13. Percent of Class Represented by Amount in Row (11) 31.9% - ------------------------------------------------------------------------------ 14. Type of Reporting Person OO - ------------------------------------------------------------------------------ 2 SCHEDULE 13D - --------------------------------- -------------------------- CUSIP NO. 09066H104 Page 3 of 14 Pages - --------------------------------- -------------------------- - ------------------------------------------------------------------------------ 1. Name of Reporting Person Genstar Capital Partners II, L.P. - ------------------------------------------------------------------------------ 2. Check the Appropriate Box if a Member of a Group (a) [_] (b) [X] - ------------------------------------------------------------------------------ 3. SEC Use Only - ------------------------------------------------------------------------------ 4. Source of Funds AF,OO - ------------------------------------------------------------------------------ 5. Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [_] - ------------------------------------------------------------------------------ 6. Citizenship or Place of Organization Delaware - ------------------------------------------------------------------------------ 7. Sole Voting Power Number of -0- shares of Common Stock Shares ----------------------------------------------------------- 8. Shared Voting Power Beneficially -3,200,553- shares of Common Stock (includes 1,262,542 Owned By shares of Common Stock issuable upon exercise of Warrants) ----------------------------------------------------------- Each 9. Sole Dispositive Power Reporting -0- shares of Common Stock Person ----------------------------------------------------------- 10. Shared Dispositive Power With -3,200,553- shares of Common Stock (includes 1,262,542 shares of Common Stock issuable upon exercise of Warrants) - ------------------------------------------------------------------------------ 11. Aggregate Amount Beneficially Owned by Each Reporting Person -3,200,553- shares of Common Stock (includes 1,262,542 shares of Common Stock issuable upon exercise of Warrants) - ------------------------------------------------------------------------------ 12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [_] - ------------------------------------------------------------------------------ 13. Percent of Class Represented by Amount in Row (11) 31.9% - ------------------------------------------------------------------------------ 14. Type of Reporting Person PN - ------------------------------------------------------------------------------ 3 SCHEDULE 13D - --------------------------------- ---------------------------- CUSIP NO. 09066H104 Page 4 of 14 Pages - --------------------------------- ---------------------------- - ------------------------------------------------------------------------------ 1. Name of Reporting Person Stargen II LLC - ------------------------------------------------------------------------------ 2. Check the Appropriate Box if a Member of a Group (a) [_] (b) [X] - ------------------------------------------------------------------------------ 3. SEC Use Only - ------------------------------------------------------------------------------ 4. Source of Funds AF,OO - ------------------------------------------------------------------------------ 5. Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [_] - ------------------------------------------------------------------------------ 6. Citizenship or Place of Organization Delaware - ------------------------------------------------------------------------------ 7. Sole Voting Power Number of -0- shares of Common Stock Shares ----------------------------------------------------------- 8. Shared Voting Power Beneficially -57,480- shares of Common Stock (includes 24,458 Owned By shares of Common Stock issuable upon exercise of Warrants) ----------------------------------------------------------- Each 9. Sole Dispositive Power Reporting -0- shares of Common Stock Person ----------------------------------------------------------- 10. shared dispositive power With -57,480- shares of Common Stock (includes 24,458 shares of Common Stock issuable upon exercise of Warrants) - ------------------------------------------------------------------------------ 11. Aggregate Amount Beneficially Owned by Each Reporting Person -57,480- shares of Common Stock (includes 24,458 shares of Common Stock issuable upon exercise of Warrants) - ------------------------------------------------------------------------------ 12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [_] - ------------------------------------------------------------------------------ 13. Percent of Class Represented by Amount in Row (11) 0.7% - ------------------------------------------------------------------------------ 14. Type of Reporting Person OO - ------------------------------------------------------------------------------ SCHEDULE 13D - --------------------------------- ---------------------------- CUSIP NO. 09066H104 Page 5 of 14 Pages - --------------------------------- ---------------------------- - ------------------------------------------------------------------------------ 1. Name of Reporting Person Jean-Pierre L. Conte - ------------------------------------------------------------------------------ 2. Check the Appropriate Box if a Member of a Group (a) [_] (b) [X] - ------------------------------------------------------------------------------ 3. SEC Use Only - ------------------------------------------------------------------------------ 4. Source of Funds PF, AF - ------------------------------------------------------------------------------ 5. Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [_] - ------------------------------------------------------------------------------ 6. Citizenship or Place of Organization United States of America - ------------------------------------------------------------------------------ 7. Sole Voting Power Number of -15,000- shares of Common Stock Shares ----------------------------------------------------------- 8. Shared Voting Power Beneficially -3,273,033- shares of Common Stock (includes Owned By 1,287,000 shares of Common Stock issuable upon exercise of Warrants) Each ----------------------------------------------------------- Reporting 9. Sole Dispositive Power Person -15,000- shares of Common Stock With ----------------------------------------------------------- 10. Shared Dispositive Power -3,273,033- shares of Common Stock (includes 1,287,000 shares of Common Stock issuable upon exercise of Warrants) - ------------------------------------------------------------------------------ 11. Aggregate Amount Beneficially Owned by Each Reporting Person -3,288,033- shares of Common Stock (includes 1,287,000 shares of Common Stock issuable upon exercise of Warrants) - ------------------------------------------------------------------------------ 12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [_] - ------------------------------------------------------------------------------ 13. Percent of Class Represented by Amount in Row (11) 32.7% - ------------------------------------------------------------------------------ 14. Type of Reporting Person IN - ------------------------------------------------------------------------------ 5 SCHEDULE 13D - --------------------------------- ---------------------------- CUSIP NO. 09066H104 Page 6 of 14 Pages - --------------------------------- ---------------------------- - ------------------------------------------------------------------------------ 1. Name of Reporting Person Richard F. Hoskins - ------------------------------------------------------------------------------ 2. Check the Appropriate Box if a Member of a Group (a) [_] (b) [X] - ------------------------------------------------------------------------------ 3. SEC Use Only - ------------------------------------------------------------------------------ 4. Source of Funds PF, AF - ------------------------------------------------------------------------------ 5. Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [_] - ------------------------------------------------------------------------------ 6. Citizenship or Place of Organization United States of America - ------------------------------------------------------------------------------ 7. Sole Voting Power Number of -16,667- shares of Common Stock Shares ----------------------------------------------------------- 8. Shared Voting Power Beneficially -3,258,033- shares of Common Stock (includes Owned By 1,287,000 shares of Common Stock issuable upon exercise of Warrants) ----------------------------------------------------------- Each 9. Sole Dispositive Power Reporting -16,667- shares of Common Stock Person ----------------------------------------------------------- 10. Shared Dispositive Power With -3,258,033- shares of Common Stock (includes 1,287,000 shares of Common Stock issuable upon exercise of Warrants) - ------------------------------------------------------------------------------ 11. Aggregate Amount Beneficially Owned by Each Reporting Person -3,274,700- shares of Common Stock (includes 1,287,000 shares of Common Stock issuable upon exercise of Warrants) - ------------------------------------------------------------------------------ 12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [_] - ------------------------------------------------------------------------------ 13. Percent of Class Represented by Amount in Row (11) 32.6% - ------------------------------------------------------------------------------ 14. Type of Reporting Person IN - ------------------------------------------------------------------------------ 6 SCHEDULE 13D - --------------------------------- ---------------------------- CUSIP NO. 09066H104 Page 7 of 14 Pages - --------------------------------- ---------------------------- - ------------------------------------------------------------------------------ 1. Name of Reporting Person Richard D. Paterson - ------------------------------------------------------------------------------ 2. Check the Appropriate Box if a Member of a Group (a) [_] (b) [X] - ------------------------------------------------------------------------------ 3. SEC Use Only - ------------------------------------------------------------------------------ 4. Source of Funds PF, AF - ------------------------------------------------------------------------------ 5. Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [_] - ------------------------------------------------------------------------------ 6. Citizenship or Place of Organization Canada - ------------------------------------------------------------------------------ 7. Sole Voting Power Number of -16,667- shares of Common Stock Shares ----------------------------------------------------------- 8. Shared Voting Power Beneficially -3,258,033- shares of Common Stock (includes Owned By 1,287,000 shares of Common Stock issuable upon exercise of Warrants) ----------------------------------------------------------- Each 9. Sole Dispositive Power Reporting -16,667- shares of Common Stock Person ----------------------------------------------------------- 10. Shared Dispositive Power With -3,258,033- shares of Common Stock (includes 1,287,000 shares of Common Stock issuable upon exercise of Warrants) - ------------------------------------------------------------------------------ 11. Aggregate Amount Beneficially Owned by Each Reporting Person -3,274,700- shares of Common Stock (includes 1,287,000 shares of Common Stock issuable upon exercise of Warrants) - ------------------------------------------------------------------------------ 12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [_] - ------------------------------------------------------------------------------ 13. Percent of Class Represented by Amount in Row (11) 32.6% - ------------------------------------------------------------------------------ 14. Type of Reporting Person IN - ------------------------------------------------------------------------------ 7 SCHEDULE 13D - --------------------------------- ---------------------------- CUSIP NO. 09066H104 Page 8 of 14 Pages - --------------------------------- ---------------------------- - ------------------------------------------------------------------------------ 1. Name of Reporting Person Robert J. Weltman - ------------------------------------------------------------------------------ 2. Check the Appropriate Box if a Member of a Group (a) [_] (b) [X] - ------------------------------------------------------------------------------ 3. SEC Use Only - ------------------------------------------------------------------------------ 4. Source of Funds PF, AF - ------------------------------------------------------------------------------ 5. Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [_] - ------------------------------------------------------------------------------ 6. Citizenship or Place of Organization United States of America - ------------------------------------------------------------------------------ 7. Sole Voting Power Number of -3,333- shares of Common Stock Shares ----------------------------------------------------------- 8. Shared Voting Power Beneficially -0- shares of Common Stock Owned By ----------------------------------------------------------- Each 9. Sole Dispositive Power Reporting -3,333- shares of Common Stock Person ----------------------------------------------------------- 10. Shared Dispositive Power With -0- shares of Common Stock - ------------------------------------------------------------------------------ 11. Aggregate Amount Beneficially Owned by Each Reporting Person -3,333- shares of Common Stock - ------------------------------------------------------------------------------ 12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [_] - ------------------------------------------------------------------------------ 13. Percent of Class Represented by Amount in Row (11) 0.0% - ------------------------------------------------------------------------------ 14. Type of Reporting Person IN - ------------------------------------------------------------------------------ 8 This Amendment No. 5 to Schedule 13D ("Amendment No. 5") amends the Schedule 13D filed with the Securities and Exchange Commission (the "Commission") on January 20, 2000, as amended (collectively, the "Schedule 13D") by Genstar Capital LLC, a Delaware limited liability company ("Genstar Capital"), Genstar Capital Partners II, L.P., a Delaware limited partnership ("Genstar Capital Partners"), Stargen II LLC, a Delaware limited liability company ("Stargen"), Jean-Pierre L. Conte, an individual ("Mr. Conte"), Richard F. Hoskins, an individual ("Mr. Hoskins"), Richard D. Paterson, an individual ("Mr. Paterson") and Robert J. Weltman, an individual ("Mr. Weltman" and, together with Genstar Capital, Genstar Capital Partners, Stargen, Mr. Conte, Mr. Hoskins and Mr. Paterson, the "Reporting Persons"), relating to shares of common stock, par value $0.001 per share (the "Common Stock"), of BioSource International, Inc., a Delaware corporation ("BioSource" or the "Company"). Unless otherwise indicated, all capitalized terms used herein but not defined herein shall have the same meanings as set forth in the Schedule 13D. Item 3. Source and Amount of Funds. -------------------------- Item 3 to the Schedule 13D is hereby amended to add the following information: Genstar Capital Partners, Messrs. Conte, Hoskins, Paterson and Weltman purchased 233,333, 30,000, 16,667, 16,667 and 3,333 of the Shares, respectively, at $15 per share or aggregate purchase prices of $3,499,995, $450,000, $250,005, $250,005 and $49,995, respectively. The funds used by Genstar Capital Partners were obtained from capital contributions of its partners. The funds used by Messrs. Conte, Hoskins, Paterson and Weltman were obtained from their respective personal funds. The funds were delivered to the Company on September 29, 2000. The purchase was completed on October 25, 2000 upon receipt of certain regulatory approvals. Item 4. Purpose of the Transaction. -------------------------- Item 4 to the Schedule 13D is hereby amended to add the following information: Pursuant to the Amendment to Securities Purchase Agreement dated September 28, 2000 (the "Amendment") by and among BioSource, Genstar Capital Partners, Mr. Conte, Mr. Hoskins, Mr. Paterson and Mr. Weltman, (i) Genstar Capital Partners purchased 233,333 of the Shares, (ii) Mr. Conte purchased 30,000 of the Shares, (iii) Mr. Hoskins purchased 16,667 of the Shares, (iv) Mr. Paterson purchased 16,667 of the Shares and (v) Mr. Weltman purchased 3,333 of the Shares. The funds for the purchase were delivered to BioSource on September 29, 2000, with the purchase occurring on October 25, 2000. A copy of the Amendment is attached hereto as Exhibit 4 and is incorporated by reference herein. A copy of the Second Amendment to the Investor Rights Agreement, which provides that upon closing of the purchases of Shares, Messrs. Conte, Hoskins, Paterson and Weltman shall be parties to the Investor Rights Agreement and that the Shares purchased by each of them shall constitute "Registrable Securities" under the Investor Rights Agreement, is attached hereto as Exhibit 5 and is incorporated by reference herein. 9 Item 5. Interest in Securities of the Issuer. ------------------------------------ Item 5 to the Schedule 13D is hereby amended to add the following information: (a) and (b). As a result of the purchase of the shares of Common Stock described below under Item 5(c), Genstar Capital Partners beneficially owns 3,200,553 shares of Common Stock, which represents 31.9% of the Common Stock outstanding (assuming exercise of the Warrants held by Genstar Capital Partners). As a result of the purchase of the shares of Common Stock described below under Item 5(c), Stargen beneficially owns 57,480 shares of Common Stock, which represents 0.7% of the Common Stock outstanding (assuming exercise of the Warrants held by Stargen). In addition to the Shares beneficially owned by Genstar Capital Partners and Stargen, Mr. Conte holds 30,000 shares of Common Stock in revocable trusts for the benefit of Mr. Conte and his wife, which represents less than 0.1% of the Common Stock outstanding, Mr. Hoskins holds 16,667 shares of Common Stock in a revocable trust for the benefit of Mr. Hoskins and his family, which represents less than 0.1% of the Common Stock outstanding, Mr. Paterson holds 16,667 shares of Common Stock in a revocable trust for the benefit of Mr. Paterson and his family, which represents less than 0.1% of the Common Stock outstanding, and Mr. Weltman beneficially owns 3,333 shares of Common Stock directly, which represents less than 0.1% of the Common Stock outstanding. As a result of the purchase of the shares of Common Stock described below under Item 5(c), the Reporting Persons beneficially own 3,324,700 shares of Common Stock, which represents 33.1% of the Common Stock outstanding (assuming exercise of the Warrants held by Genstar Capital Partners and Stargen). Genstar Capital Partners has the sole power to dispose or direct the disposition of the Warrants and shares of Common Stock which it holds directly or the shares of Common Stock issued upon exercise of such Warrants. Genstar Capital Partners does not have the power to vote or direct the vote of any of the shares of Common Stock which it would own upon exercise of such Warrants prior to the receipt of such shares of Common Stock upon exercise of such Warrants. Genstar Capital Partners has the power to vote or direct the vote of the shares of Common Stock which it holds directly. Genstar Capital is the sole general partner of Genstar Capital Partners and in such capacity may be deemed to have the power to dispose or direct the disposition of the Warrants and shares of Common Stock held by Genstar Capital Partners, and shares of Common Stock which Genstar Capital Partners would hold upon exercise of such Warrants, and to vote or direct the vote of such shares of Common Stock. Stargen has the sole power to dispose or direct the disposition of the Warrants and shares of Common Stock which it holds directly and the shares of Common Stock issued upon exercise of such Warrants. Stargen does not have the power to vote or direct the vote of any of the shares of Common Stock which it would own upon exercise of such Warrants prior to the receipt of such shares of Common Stock upon exercise of such Warrants. Stargen has the power to vote or direct the vote of the shares of Common Stock which it holds directly. Messrs. Conte, Hoskins and Paterson are the managers and managing directors of Genstar Capital and are members of Stargen, and Mr. Paterson is the Administrative Member of Stargen, and in such capacity may be deemed to have the power to dispose or direct the disposition of the 10 Warrants and shares of Common Stock held by the Investors, and shares of Common Stock which the Investors would own upon exercise of such Warrants, and may be deemed to have the power to vote or direct the vote of such shares of Common Stock. Mr. Weltman is a Vice President and a member (but not a managing member) of Genstar Capital and a member (but not a managing member) of Stargen. Mr. Weltman does not have power to vote or dispose of, or to direct the voting or disposition of, any securities beneficially owned by Genstar Capital or Stargen. Mr. Weltman disclaims that he beneficially owns any shares of Common Stock beneficially owned by Genstar Capital Partners or Stargen, except to the extent of his economic interest therein. Mr. Conte has the sole power to dispose or direct the disposition of, and to vote or direct the vote of, 15,000 of the shares of Common Stock that he holds in trust for the benefit of himself and his wife, and shared power with his wife to dispose or direct the disposition of, and to vote or direct the vote of, the remaining 15,000 of the shares of Common Stock that he holds in trust for the benefit of himself and his wife. Each of Messrs. Hoskins and Paterson has the sole power to dispose or direct the disposition of, and to vote or direct he vote of, the shares of Common Stock that each of them holds in trust for the benefit of himself and his family. Mr. Weltman has the sole power to dispose or direct the disposition of, and to vote or direct the vote of, the shares of Common Stock that he holds directly. The Reporting Persons may be deemed to be acting as a group in relation to their respective holdings in BioSource, but do not affirm the existence of any such group. Except as set forth in this Item 5(a)-(b), each of the persons named in this Item 5(a)-(b) disclaims beneficial ownership of any Common Stock owned beneficially or of record by any other person named in this Item 5(a)-(b). (c) Pursuant to the Amendment (i) Genstar Capital Partners purchased 233,333 of the Shares, (ii) Mr. Conte purchased 30,000 of the Shares, (iii) Mr. Hoskins purchased 16,667 of the Shares, (iv) Mr. Paterson purchased 16,667 of the Shares and (v) Mr. Weltman purchased 3,333 of the Shares. The funds for the purchase were delivered to BioSource on September 29, 2000, with the purchase occurring on October 25, 2000. A copy of the Amendment is attached hereto as Exhibit 4 and is incorporated by reference herein. Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to ------------------------------------------------------------------------ Securities of the Issuer. ------------------------ Item 6 to the Schedule 13D is hereby amended to add the following information: Pursuant to the Amendment (i) Genstar Capital Partners purchased 233,333 of the Shares, (ii) Mr. Conte purchased 30,000 of the Shares, (iii) Mr. Hoskins purchased 16,667 of the Shares, (iv) Mr. Paterson purchased 16,667 of the Shares and (v) Mr. Weltman purchased 3,333 of the Shares. The funds for the purchase were delivered to BioSource on September 29, 2000, with the purchase occurring on October 25, 2000. A copy of the Amendment is attached hereto as Exhibit 4 and is incorporated by reference herein. A copy of the Second Amendment to the Investor Rights Agreement, which provides that upon closing of the purchases of Shares, Messrs. Conte, Hoskins, Paterson and Weltman shall be parties to the Investor Rights Agreement and that the Shares purchased by each of them shall constitute "Registrable Securities" under the Investor Rights Agreement, is attached hereto as Exhibit 5 and is incorporated by reference herein. 11 Item 7. Material to be Filed as Exhibits. -------------------------------- Exhibit 1 Joint Filing Agreement (incorporated by reference to the Schedule 13D). Exhibit 2 Power of Attorney for Robert J. Weltman (incorporated by reference to the Schedule 13D). Exhibit 3 Power of Attorney for each of Messrs. Hoskins and Paterson. Exhibit 4 Amendment to Securities Purchase Agreement by and among BioSource, Genstar Capital Partners and Messrs. Conte, Hoskins, Paterson and Weltman dated as of September 28, 2000. Exhibit 5 Second Amendment, dated as of September 28, 2000, by and among BioSource, Genstar Capital Partners, Stargen, Messrs. Conte, Hoskins, Paterson and Weltman, Russell D. Hays and George Uveges, to the Investor Rights Agreement, dated as of February 15, 2000, by and among BioSource, Genstar Capital Partners and Stargen. 12 SIGNATURE --------- After reasonable inquiry and to the best of each of the undersigned's knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: October 25, 2000 GENSTAR CAPITAL LLC By: /s/ Jean-Pierre L. Conte ------------------------------------------ Name: Jean-Pierre L. Conte Its: Managing Member GENSTAR CAPITAL PARTNERS II, L.P. By: Genstar Capital LLC, its general partner By: /s/ Jean-Pierre L. Conte ------------------------------------------ Name: Jean-Pierre L. Conte Its: Managing Member STARGEN II LLC By: /s/ Jean-Pierre L. Conte ------------------------------------------ Name: Jean-Pierre L. Conte Its: Member /s/ Jean-Pierre L. Conte ---------------------------------------------- Jean-Pierre L. Conte /s/ Jean-Pierre L. Conte ---------------------------------------------- Jean-Pierre L. Conte Attorney-in-fact for Richard F. Hoskins /s/ Jean-Pierre L. Conte ---------------------------------------------- Jean-Pierre L. Conte Attorney-in-fact for Richard D. Paterson /s/ Jean-Pierre L. Conte ---------------------------------------------- Jean-Pierre L. Conte Attorney-in-fact for Robert J. Weltman 13 EXHIBIT INDEX ------------- Exhibit 1 Joint Filing Agreement (incorporated by reference to the Schedule 13D). Exhibit 2 Power of Attorney for Robert J. Weltman (incorporated by reference to the Schedule 13D). Exhibit 3 Power of Attorney for each of Messrs. Hoskins and Paterson. Exhibit 4 Amendment to Securities Purchase Agreement by and among BioSource, Genstar Capital Partners and Messrs. Conte, Hoskins, Paterson and Weltman dated as of September 28, 2000. Exhibit 5 Second Amendment, dated as of September 28, 2000, by and among BioSource, Genstar Capital Partners, Stargen, Messrs. Conte, Hoskins, Paterson and Weltman, Russell D. Hays and George Uveges, to the Investor Rights Agreement, dated as of February 15, 2000, by and among BioSource, Genstar Capital Partners and Stargen. 14 EX-99.3 2 0002.txt POWER OF ATTORNEY EXHIBIT 3 POWER OF ATTORNEY ----------------- Know all men by these presents that each of Richard F. Hoskins and Richard D. Paterson does hereby make, constitute and appoint Jean-Pierre L. Conte as a true and lawful attorney-in-fact of the undersigned with full powers of substitution and revocation, for and in the name, place and stead of the undersigned, (both in the undersigned's individual capacity and as a member of any limited liability company or partner of any partnership for which the undersigned is otherwise authorized to sign), to execute and deliver such forms as may be required to be filed from time to time with the Securities and Exchange Commission with respect to any investments of Genstar Capital LLC, Genstar Capital Partners II, L.P. and Stargen II LLC or the undersigned (including any amendments or supplements to any reports from schedules previously filed by such persons or entities) including any joint filing agreements or joint filer information statements in connection therewith with respect to BioSource International, Inc.: (i) pursuant to Sections 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, including without limitation, Schedules 13D and 13G, statements on Form 3, Form 4 and Form 5 and (ii) in connection with any applications for EDGAR access codes, including without limitation the Form ID. /s/ Richard F. Hoskins --------------------------- Name: Richard F. Hoskins /s/ Richard D. Paterson --------------------------- Name: Richard D. Paterson Dated: October 6, 2000 EX-99.4 3 0003.txt AMENDMENT TO SECURITIES PURCHASE AGREEMENT Exhibit 4 AMENDMENT TO SECURITIES PURCHASE AGREEMENT THIS AMENDMENT TO SECURITIES PURCHASE AGREEMENT (this "Amendment") is entered into as this 28th day of September, 2000, by and among BioSource International, Inc., a Delaware corporation (the "Company"), Genstar Capital Partners II, L.P., a Delaware limited partnership ("Genstar"), Jean-Pierre Conte, Richard Hoskins, Richard Paterson and Robert Weltman. Genstar, together with Messrs. Conte, Hoskins, Paterson and Weltman are sometimes collectively referred to herein as the "Purchasers." WHEREAS, the Company and Genstar entered into the Securities Purchase Agreement (the "Agreement"), which provided for the purchase by Genstar and such other persons to whom Genstar assigned its rights pursuant to Section 4.5 of the Agreement, would purchase 300,000 shares of Common Stock; WHEREAS, the Company and Genstar desire to amend the Agreement to effectuate the previously contemplated assignment by Genstar to Messrs. Conte, Hoskins, Paterson and Weltman. NOW, THEREFORE, in consideration of the promises and mutual covenants and agreements hereinafter contained, the Company and Purchaser hereby agree as follows: 1. Capitalized terms used herein without definition shall have the meanings set forth in the Agreement. 2. Article I of the Agreement is hereby amended to add the following: "The number of shares of Common Stock to be acquired by, and the purchase price to be paid by, each Purchaser is set forth on Schedule A attached hereto. At the Closing, each Purchaser will pay the amount set forth the amount set forth on Schedule A and the Company shall instruct the transfer agent to immediately deliver to each Purchaser a stock certificate or certificates, in definitive form, registered in the name of such Purchaser, representing the Shares as set forth on Schedule A." 3. Each Purchaser hereby makes, severally and not jointly, the representations and warranties set forth in Section 2.2, and each Purchaser agrees, severally and not jointly, to be bound by and fully perform all of Purchaser's covenants under the Agreement. The Company agrees to treat each Purchaser as a "Purchaser" under the Agreement. 4. Except as specifically modified by this Amendment, the Agreement shall remain in full force and effect and is hereby ratified and confirmed. IN WITNESS WHEREOF, the parties hereto have caused this Amendment to Securities Purchase Agreement to be duly executed as of the date first above written. BIOSOURCE INTERNATIONAL, INC. By: /s/ Russell D. Hays ------------------------------ Name: Title: GENSTAR CAPITAL PARTNERS II, L.P. By: Genstar Capital LLC Its: General Partner By: /s/ Jean-Pierre Conte ------------------------------ Name: Title: JEAN-PIERRE CONTE /s/ Jean-Pierre Conte ----------------------------------- RICHARD HOSKINS /s/ Richard Hoskins ----------------------------------- RICHARD PATERSON /s/ Richard Paterson ----------------------------------- ROBERT WELTMAN /s/ Robert Weltman ----------------------------------- Schedule A
- ---------------------------------------------------------------------------------------------------- Name Number of Shares Purchase Price Amount ---- ---------------- --------------------- - ---------------------------------------------------------------------------------------------------- Genstar Capital Partners II, L.P. 233,333 $3,499,995 - ---------------------------------------------------------------------------------------------------- Jean-Pierre Conte 30,000 $ 450,000 - ---------------------------------------------------------------------------------------------------- Richard Hoskins 16,667 $ 250,005 - ---------------------------------------------------------------------------------------------------- Richard Paterson 16,667 $ 250,005 - ---------------------------------------------------------------------------------------------------- Robert Weltman 3,333 $ 49,995 - ----------------------------------------------------------------------------------------------------
EX-99.5 4 0004.txt SECOND AMENDMENT TO INVESTOR RIGHTS AGREEMENT EXHIBIT 5 SECOND AMENDMENT TO INVESTOR RIGHTS AGREEMENT THIS SECOND AMENDMENT (this "Second Amendment"), dated as of September 28, 2000, by and among BIOSOURCE INTERNATIONAL, INC., a corporation organized under the laws of the State of Delaware (the "Company"); GENSTAR CAPITAL PARTNERS II, L.P., a Delaware limited partnership ("Genstar Capital Partners"); STARGEN II LLC, a Delaware limited liability company ("Stargen"); RUSSELL D. HAYS, an individual ("Hays"); GEORGE UVEGES, an individual ("Uveges"); JEAN-PIERRE L. CONTE, an individual ("Conte"); RICHARD F. HOSKINS, an individual ("Hoskins"); RICHARD D. PATERSON, an individual ("PATERSON"); and ROBERT J. WELTMAN, an individual ("WELTMAN" and, together with Conte, Hoskins and Paterson, the "New Investors" and, together with Conte, Hoskins, Paterson, Hays, Uveges, Genstar Capital Partners and Stargen, the "Investors"). RECITALS WHEREAS, the Company, Genstar Capital Partners, Stargen, Hays and Uveges are parties to that certain Investor Rights Agreement dated February 15, 2000, as amended by the Amendment to Investor Rights Agreement dated as of September 18, 2000 (as so amended, the "Agreement," capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Agreement); WHEREAS, the Company, on the one hand, and Genstar Capital Partners and the New Investors, on the other hand, have entered into that certain purchase agreement dated September 15, 2000, as amended on September 28, 2000 (as so amended, the "Purchase Agreement"), pursuant to which the Company has agreed, upon the terms and subject to the conditions contained therein, to issue and sell to Genstar Capital Partners and the New Investors an aggregate of 300,000 shares of the Company's Common Stock, par value $0.001 per share (the "Shares"); and WHEREAS, in connection with the transactions contemplated by the Purchase Agreement, the Company and the Investors desire to amend the Agreement to provide to Genstar Capital Partners and the New Investors, upon closing of the purchase of the Shares pursuant to the Purchase Agreement, certain registration rights with respect to the Shares under the Securities Act, and applicable state securities laws. AGREEMENT NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Investors, intending to be legally bound, hereby agree as follows: 1. Amendment to Definitions. Section 1(b) of the Agreement is hereby amended to read as follows: (b) "Registrable Securities" means (i) the shares of Common Stock of the Company issued to Genstar Capital Partners and the Investors pursuant to certain purchase agreements dated September 15, 2000 and September 18, 2000, respectively, by and among the Company, Genstar Capital Partners and the New Investors, on the one hand, and the Company, Russell D. Hays and George Uveges, on the other hand, and (ii) the shares of Common Stock of the Company issued or issuable to Genstar Capital Partners and Stargen upon conversion of the Series B Shares or upon exercise of the Warrants and any shares of capital stock issued or issuable, from time to time (with any adjustments), as a distribution on or in exchange for or otherwise with respect to the foregoing. Section 1 of the Agreement is hereby amended to add the following new subsections: (d) "Investors" shall mean each of Genstar Capital Partners II, L.P. ("Genstar Capital Partners"), Stargen II LLC ("Stargen"), Russell D. Hays, George Uveges, Jean-Pierre L. Conte, Richard F. Hoskins, Richard D. Paterson and Robert J. Weltman; provided, however, that none of Russell D. Hays, George Uveges, Jean-Pierre L. Conte, Richard F. Hoskins, Richard D. Paterson or Robert J. Weltman shall be deemed to be an "Investor" under Sections 10, 11, 12 or 13 of this Agreement. (e) "New Investors" shall mean each of Jean-Pierre L. Conte, Richard F. Hoskins, Richard D. Paterson and Robert J. Weltman. 2. Joinder. The Company and the Investors hereby agree that (i) the New Investors shall be deemed to be parties to the Agreement; and (ii) Genstar Capital Partners and the New Investors shall be entitled to all of the rights, benefits and privileges of Investors, and shall observe all of the obligations of Investors, under the Agreement with respect to the Shares held by each of them; provided, however, that none of the New Investors shall be deemed to be an "Investor" under Sections 10, 11, 12 or 13 of the Agreement, nor shall any of the New Investors be entitled to any of the rights, benefits or privileges inuring to the benefit of "Investors" under Sections 10, 11, 12 or 13 of the Agreement, such rights, benefits and privileges being reserved for the exclusive benefit of Genstar Capital Partners and Stargen. 3. Entire Agreement. This Amendment supersedes the Agreement solely with respect to the subject matter herein. All terms and provisions of the Agreement not affected by this Amendment remain binding and enforceable between Investors and the Company. [Remainder of page intentionally left blank] 2 IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed as of the date first above written. BIOSOURCE INTERNATIONAL, INC. By: /s/ Russell D. Hays -------------------------------------- GENSTAR CAPITAL PARTNERS II, L.P. By: Genstar Capital LLC Its General Partner By: /s/ Jean-Pierre L. Conte -------------------------------------- Jean-Pierre L. Conte Managing Director STARGEN II LLC By: /s/ Jean-Pierre L. Conte -------------------------------------- Jean-Pierre L. Conte Managing Director /s/ Russell D. Hays ----------------------------------------- Russell D. Hays /s/ George Uveges ----------------------------------------- George Uveges /s/ Jean-Pierre L. Conte ----------------------------------------- Jean-Pierre L. Conte /s/ Richard F. Hoskins ----------------------------------------- Richard F. Hoskins 3 /s/ Richard D. Paterson ------------------------------------ Richard D. Paterson /s/ Robert J. Weltman ------------------------------------ Robert J. Weltman 4 -----END PRIVACY-ENHANCED MESSAGE-----